Bacterial contamination in platelet concentrates

“…We also appropriately increased residual risk of platelet bacterial contamination to account for large differences in safety measures between the two countries. The reporting of high rates of detection of bacterial contamination in all three labile components in similar settings, as described by studies performed in Germany and Croatia [19][20][21], does not reconcile easily with very low rates of adverse events in hemovigilance data [22]. By varying, simultaneously, the probability of contamination in plasma products and death due to sepsis, we showed that a specific joint probability of death from sepsis may lead to disparate ICERs in our model.…”

Section: Discussionmentioning

confidence: 49%

Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis

Agapova

Lachert

Brojer

et al. 2015

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Mirasol® pathogen reduction technology (PRT) uses UV light and riboflavin to chemically inactivate pathogens and white blood cells in blood components. In the EU, Mirasol PRT is CE-marked for both plasma and platelet treatment. In Poland, the decision to introduce PRT treatment of the national supply of fresh frozen plasma has spurred interest in evaluating the cost-effectiveness of this strategy. Methods: A decision-analytic model evaluated the incremental costs and benefits of introducing PRT to the existing blood safety protocols in Poland. Results: Addition of PRT treatment of plasma to current screening in Poland is estimated to cost 2.595 million PLN per quality-adjusted life year (QALY) (610,000 EUR/QALY); treating both plasma and platelet components in addition to current safety interventions had a lower cost of 1.480 million PLN/QALY (348,000 EUR/QALY). Conclusions: The results suggest that in Poland the cost per QALY of PRT is high albeit lower than found in previous economic analyses of PRT and nucleic acid testing in North America. Treating both platelets and plasma components is more cost-effective than treating plasma alone. Wide confidence intervals indicate high uncertainty; to improve the precision of the health economic evaluation of PRT, additional hemovigilance data are needed.

show abstract

“…However, platelet concentrates expire for transfusion purposes after a maximum shelf-life of 5 days, after which they can still be used as a cell culture supplement. Since platelet concentrates are stored at room temperature, there is a risk of bacterial contamination (Pietersz et al, 2014). Thus, the shelf-life (in Germany) is currently restricted to 4 days and can be extended to 5 days in case of negative bacterial testing.…”

Section: Alternatives To Fbsmentioning

confidence: 99%